Abstract:We investigate a two-strain disease model with amplification to simulate the prevalence of drug-susceptible (s) and drug-resistant (m) disease strains. Drug resistance first emerges when drug-susceptible strains mutate and become drug-resistant, possibly as a consequence of inadequate treatment, i.e. amplification. In this case, the drug-susceptible and drug-resistant strains are coupled. We perform a dynamical analysis of the resulting system and find that the model contains three equilibrium points: a disease-free equilibrium; a mono-existent disease-endemic equilibrium at which only the drug-resistant strain persists; and a co-existent disease-endemic equilibrium where both the drug-susceptible and drug-resistant strains persist. We found two basic reproduction numbers: one associated with the drug-susceptible strain (R0s); the other with the drug-resistant strain (R0m), and showed that at least one of the strains can spread in a population if max[R0s,R0m]>1. Furthermore, we also showed that if R0m>max[R0s,1], the drug-susceptible strain dies out but the drug-resistant strain persists in the population (mono-existent equilibrium); however if R0s>max[R0m,1], then both the drug-susceptible and drug-resistant strains persist in the population (co-existent equilibrium). We conducted a local stability analysis of the system equilibrium points using the Routh-Hurwitz conditions and a global stability analysis using appropriate Lyapunov functions. Sensitivity analysis was used to identify the key model parameters that drive transmission through calculation of the partial rank correlation coefficients (PRCCs). We found that the contact rate of both strains had the largest influence on prevalence. We also investigated the impact of amplification and treatment/recovery rates of both strains on the equilibrium prevalence of infection; results suggest that poor quality treatment/recovery makes coexistence more likely and increases the relative abundance of resistant infections.

Global dynamics for a drug-sensitive and drug-resistant mixed strains of HIV infection model with saturated incidence and distributed delays

The global dynamics in a wild-type and drug-resistant HIV infection model with saturated incidence

A Delay-Dependent Model with HIV Drug Resistance During Therapy

Bifurcation analysis and chaos for a double-strains HIV coinfection model with intracellular delays, saturated incidence and Logistic growth

Mathematical analysis of an HIV model with latent reservoir, delayed CTL immune response and immune impairment

Global threshold dynamics in an HIV virus model with nonlinear infection rate and distributed invasion and production delays.

Global Stability of Infection-Free State and Endemic Infection State of a Modified Human Immunodeficiency Virus Infection Model.

Dynamics Analysis and Simulation of a Modified HIV Infection Model with a Saturated Infection Rate.

Global stability of an HIV-1 model with distributed intracellular delays and a combination therapy.

GLOBAL RESULTS FOR AN HIV/AIDS MODEL WITH MULTIPLE SUSCEPTIBLE CLASSES AND NONLINEAR INCIDENCE

Modelling Hiv Superinfection among Men Who Have Sex with Men

Global stability for a delayed HIV reactivation model with latent infection and Beddington–DeAngelis incidence

A Within-Host Drug Resistance Model with Continuous State-Dependent Viral Strains

GLOBAL STABILITY ANALYSIS AND PERMANENCE FOR AN HIV-1 DYNAMICS MODEL WITH DISTRIBUTED DELAYS

Mathematical analysis of a two-strain disease model with amplification

Global Stability for a Class of HIV Virus-to-cell Dynamical Model with Beddington-DeAngelis Functional Response and Distributed Time Delay.

Stability of delayed virus infection model with a general incidence rate and adaptive immune response 1

Global Stability for a Diffusive Infection Model with Nonlinear Incidence

Complete Dynamics In A Nonlocal Dispersal Two-Strain Siv Epidemic Model With Vaccinations And Latent Delays

Dynamics of an Age-Structured HIV Model with General Nonlinear Infection Rate

Modeling Within-Host Viral Dynamics: the Role of CTL Immune Responses in the Evolution of Drug Resistance